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Abstract
Summary The competitive price of generic bisphospho-
nates has had a marked effect on practice guidelines, but an
increasing body of evidence suggests that they have more
limited effectiveness than generally assumed.
Introduction The purpose of this study is to review the
impact of generic bisphosphonates on effectiveness in the
treatment of osteoporosis.
Methods This study is a literature review.
Results A substantial body of evidence indicates that many
generic formulations of alendronate are more poorly
tolerated than the proprietary preparations which results in
significantly poorer adherence and thus effectiveness.
Poorer effectiveness may result from faster disintegration
times of many generics that increase the likelihood of
adherence of particulate matter to the oesophageal mucosa.
Unfortunately, market authorisation, based on the bioequi-
valence of generics with a proprietary formulation, does not
take into account the potential concerns about safety. The
poor adherence of many generic products has implications
for guideline development, cost-effectiveness and impact of
treatment on the burden of disease.
Conclusions The impact of generic bisphosphonates
requires formal testing to re-evaluate their role in the
management of osteoporosis.
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The clinical consequences of osteoporosis are mainly the
increased incidence of fractures and their associated
morbidity and premature mortality. In addition to the
negative impact on the quality and quantity of life of the
individual, osteoporosis is a costly disease for society. The
number of fragility fractures and the societal costs
associated with the disease are expected to increase in the
future, partly due to changes in demography and improved
life expectancy and, in some countries, due to an increase in
age-specific incidence of fractures. In 1990, the number of
osteoporotic fractures in Europe was estimated to be 2.7
million, with a direct cost of €36 billion, of which €24.3
billion were accounted for by hip fractures. Costs are
expected to rise to €76.8 billion by the year 2050 [1]
because of the increasing number of the elderly in the
population.
The importance of developing treatments that reduce the
risk of fracture is evident, both from an individual and a
societal perspective, and a number of agents are available that
have been shown in randomised controlled trials to decrease
the risk of vertebral and, in some instances, non-vertebral
fracture [2, 3]. Major pharmacological interventions are the
bisphosphonates, strontium ranelate, raloxifene, denosumab
and parathyroid hormone peptides. Interventions that are
approved for the prevention and treatment of osteoporosis in
Europe are shown in Table 1. They are approved only for the
treatment of postmenopausal osteoporosis, but alendronate,
etidronate, risedronate and zoledronic acid are also approved
for the prevention and treatment of glucocorticoid-induced
osteoporosis [4, 5] and alendronate, risedronate, zoledronate
and teriparatide are approved for the treatment of osteopo-
rosis in men [3, 6].
All these interventions have been shown to reduce the
risk of vertebral fracture when given with calcium and
vitamin D supplements. Some have been shown also to
reduce the risk of non-vertebral fractures or specifically hip
fractures. Of the available options, alendronate, risedronate,
zoledronic acid, denosumab and strontium ranelate reduce
vertebral, non-vertebral and hip fractures [7–15]( s e e
Table 1). The reduction in vertebral fracture rate has been
between 50% and 70% whereas the magnitude of reduction
in non-vertebral fracture, where demonstrated, has general-
ly been smaller and in the order of 15–25%. Because of the
broader spectrum of anti-fracture efficacy, these agents are
generally regarded as preferred options in the prevention of
fractures in postmenopausal women. This distinction may
be important because once a fracture occurs, the risk of a
subsequent fracture at most common sites is increased
independently of bone mineral density, and hence, an
intervention that covers all major fracture sites is preferable.
Notwithstanding, there have been no head-to-head studies
with fracture as the primary outcome, so that direct
comparison of efficacy between agents is not possible.
For this reason, many treatment guidelines did not make a
distinction between these agents in terms of any recom-
mendations for their use [16–21].
Impact of generics
In recent years, the situation has changed markedly because
of the advent of generic bisphosphonates with a substantial
decrease in price and the impact of this on cost-
effectiveness. A pan-European study from 2004 estimated
the cost-effectiveness of branded alendronate in nine
countries [22]. In this study alendronate was shown to be
cost saving compared to no treatment in women with
osteoporosis (with or without previous vertebral fracture)
from the Nordic countries (Norway, Sweden and Denmark).
The cost-effectiveness of alendronate compared to no
treatment was also within acceptable ranges in Belgium,
France, Germany, Italy, Spain and the UK. However, with
the rapid decline in the price of the generic alendronate,
analyses based on a branded drug price have become
obsolete and would require an update. For example, in the
above-mentioned study, the annual price of branded
alendronate varied between €444/year (UK) to €651/year
(Denmark). The current drug price for alendronate is less
than €300/year in all countries and even as low as €18/year
in the UK. Revisiting the analysis using these prices
markedly improves the cost-effectiveness of alendronate
[23, 24] because of the decrease in cost (Fig. 1).
Before the advent of generic bisphosphonates, practice
guidelines in the UK did not consider first-line treatment,
and recommendations were largely based on the spectrum
Table 1 Spectrum of anti-fracture efficacy of interventions approved
in Europe [3]
Fracture outcome
Intervention Vertebral Non-vertebral Hip
Alendronate + + +
Ibandronate + +
a NCE
Denosumab + + +
Risedronate + + +
Zoledronic acid + + +
Raloxifene + NCE NCE
Strontium ranelate + + +
a
Teriparatide + + NCE
PTH (1–84) + NCE NCE
NCE no convincing effects. PTH recombinant human parathyroid
hormone
aIn subsets of patients (post hoc analysis)
214 Osteoporos Int (2012) 23:213–221of activity of the agent and side effects [16–21, 27]. As a
consequence of the marked effect of the price of interven-
tion on cost-effectiveness and the relatively stable price of
other interventions, practice guidelines in the UK and
elsewhere recommend that generic alendronate be viewed
as first-line treatment [3, 28, 29], and generic alendronate
now dominates many European markets [23]. This view,
based on cost minimisation, is sustainable provided that
cost is reduced without sacrificing effectiveness. This
appears not to be the case and may in part represent a
failure of the regulatory pathway.
Regulatory background to generics
Most health care systems today have to deal with the
challenging obligation of limiting and minimising health
expenditure. Given the increasing costs of health care, many
global initiatives [30] and national health policies worldwide
recommend therapeutic substitution. Therapeutic substitution
is the interchange of a less costly drug in place of another
treatment, based on the premise that the cheaper version has
the same therapeutic effect [31]. Usually, a generic version of
the same drug is developed and used as a strategy to reduce
rapidly prescribing costs [32, 33].
The generic forms of a reference drug are usually marketed
after the patent of the branded agent has expired, i.e. after
10 years or more. As defined by the Directive 2001/83/EC of
the European Community [34], a generic drug contains an
active component qualitatively and quantitatively identical to
the reference drug, but excipients may differ. The reference is
the original and innovative agent that has been made
available to the market and registered on the basis of a
complete registration procedure, with full quality, safety and
efficacy data. In contrast, marketing the generic form
necessitates only an abridged procedure since it does not
concern a new chemical entity. The manufacturer of a generic
drug can submit an application for marketing authorisation
built on the basis of the information provided by the full
marketing procedure of the reference drug and on proving the
bioequivalence of the two drugs, generic and reference, as
recommended by the European Medicine Agency guideline
[34]. The avoidance of studies of efficacy and safety reduces
markedly the development costs permitting price reduction
because major development costs are avoided.
Market authorisation of a generic substitute relies
heavily on the demonstration of bioequivalence. A bio-
equivalence study is a randomized clinical study, usually in
healthy volunteers, that compares the bioavailability be-
tween the test product and a reference product. For oral
agents, such as the bisphosphonates, this will include a
comparison of absorption (area under the curve, AUC), the
rate of absorption (Tmax) and peak concentration (Cmax)
based on serum concentration or more usually with the
bisphosphonates on cumulative urinary excretion (Ae)
(Fig. 2). Equivalence is inferred when, for both AUC and
Cmax, the 90% confidence interval for the ratio of
geometric means for test and reference formulations lies
within the range of 0.8–1.25 [34].
Branded vs. generic bisphosphonates
Gastrointestinal intolerance of amino-bisphosphonates is a
well recognised side effect due in part to local effects on the
Cumulative urinary excretion (µg)
300
200 Reference alendronate
Test alendronate
100
0
0 4 8 12 16 20 24 28 32 36
Time(hours)
Fig. 2 Mean cumulative urinary excretion of alendronate 70 mg by
mouth after the administration of test and reference formulations (n=
70) [redrawn from 61]
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Fig. 1 Impact of price of intervention on cost-effectiveness for a
woman from Sweden aged 65 years and a twofold increased risk of
fracture is described by the continuous line.T h eshaded area
approximates the willingness to pay by the National Institute for
Health and Clinical Excellence (NICE) in the UK. The symbols
represent the cost of generic alendronate in several EU counties
Assumed RRR=35%; Costs and effects discounted at 3%; Includes
cost in added life-years; Source, reference model of the International
Osteoporosis Foundation [25]. For other assumptions, see [26]
Osteoporos Int (2012) 23:213–221 215oesophageal or gastric mucosa. Gastrointestinal adverse
effects that have been associated with oral bisphosphonates
include dysphagia, oesophagitis, stomach ulceration and,
more arguably, oesophageal cancer [35–39]. With alendro-
nate, chemical oesophagitis may occur, promoted by an
inadequate amount of water when swallowing the pill and
failure to remain upright for some time after taking the drug
[36, 40]. These adverse effects are mitigated somewhat by
weekly or monthly rather than daily formulations but
contribute to the poor adherence associated with the long-
term management of patients with osteoporosis [41–46].
Since the introduction of generic bisphosphonates,
reports have consistently concluded that adherence is
poorer in patients who take generic alendronate than with
the original product. In an insurance claims database of
upper gastrointestinal tract outcomes in 6,962 patients
either on branded or generic alendronate for a minimum
of 3 months (10 mg daily), significantly higher discontin-
uation rates were noted with the generic versions of
alendronate as compared to the brand [47]. Incident rate
ratios (IRR) for treatment discontinuation were higher with
two generic formulations compared to the proprietary
product (IRR, 1.3; 95% CI 1.04–1.63). Adherence (medi-
cation possession ratio, >80%) was higher (IRR, 1.19; 95%
CI 1.11–1.27) and the new use of gastric medications (3.4–
4.9%) lower with branded than with the generic equivalent
(IRR, 0.71; 95% CI 0.53–0.95). Similar findings were
reported from a large Canadian claims database [48] that
examined adherence with a weekly dose (70 mg). After
adjusting for potential confounding covariates, patients who
were started on weekly oral generic alendronate remained at
a higher risk of early discontinuation compared to patients
initiated with weekly oral branded alendronate (IRR, 2.08;
95% CI 1.89–2.28) (Fig. 3).
It might be argued that the introduction of generic
alendronate resulted in a widening of the prescription
market with the inclusion of patients less motivated to
therapy and thus less compliant than formerly. This seems
unlikely given that the same phenomenon was noted when
patients established on treatment were switched from a
branded to generic formulation. Following the introduc-
tion of generic alendronate to the Canadian market in
July 2005, over 80% of patients were automatically
switched from branded to generic alendronate without
notification. An increase in the reports of adverse
effects prompted a review of the case notes of 301
women with osteoporosis aged 50 years or more who
had been established on treatment with alendronate
10 mg daily or 70 mg weekly between 2003 and 2007
[49]. The rate of adverse events resulting in the discon-
tinuation of treatment was significantly higher after the
introduction of generic alendronate than before (5.3/100
vs. 1.2/100 patient-years of exposure; p<0.001). The
majority of adverse events reported were upper gastroin-
testinal (61%). The higher rates of GI intolerance were
associated with more frequent discontinuation of treatment
Fig. 3 Kaplan–Meier curves
for the risk of early discon-
tinuation during the year fol-
lowing index date (first
dispensation of bisphospho-
nate) [48] with kind permission
from Springer Science + Business
Media BV
216 Osteoporos Int (2012) 23:213–221and significant losses of bone mineral density (BMD) at
the femoral neck and lumbar spine.
A second retrospective chart review in Germany com-
pared the effects of once weekly branded risedronate or
alendronate with generic alendronate on BMD [50]. Of 186
women with postmenopausal osteoporosis, treated for at
least 12 months, there was a significantly higher incidence
of gastrointestinal (and other) adverse events in women
taking the generic drugs. Significantly smaller increments
in BMD at the lumbar spine (p<0.05) and total hip (p<
0.01) were observed after 1 year in the group receiving
generic alendronate compared to those receiving the two
branded bisphosphonates.
Thus, the evidence available indicates that many generic
formulations are less well tolerated than the proprietary
products and that this leads to poorer adherence, in turn
associated with a poorer clinical outcome in terms of
effectiveness on BMD [51–53] and ultimately in effective-
ness on fracture outcomes [44, 51, 54–56].
Because generic drugs in developed markets are
shown to be bioequivalent, it might be assumed that
the decrease in effectiveness is a result of the poor
adherence. There is some evidence that there may be
additional effects on drug efficacy. In the case review of
Ringe et al. [50] unequal efficacy of the generic vs.
branded alendronate and risedronate was observed in the
effect on BMD: significantly lower treatment-induced
increases in BMD at the lumbar spine (p<0.05) and total
hip (p<0.01) were observed after 1 year in the group
receiving generic alendronate compared to those receiving
the two branded bisphosphonates. In the Canadian survey
[49], generic treatment was stopped because of a decrease
in BMD in a significant minority of patients. Whether
some generic products have lower efficacy remains an
open question, and poor adherence provides a plausible
reason for the apparent reduction in the effectiveness of
the generic products.
Formulation
The question arises whether poor tolerance is due to
differences in the formulation between the generics and
their branded equivalents, and there is evidence to suggest
that this is indeed the case. Mean disintegration times have
been found to be significantly faster for two generic
formulations of alendronate available in Canada compared
to branded alendronate (with or without vitamin D) or
branded risedronate [57]. Disintegration rates of several of
the generics available in Europe or the USA were similar to
those reported for tablets specifically formulated to disin-
tegrate in the mouth (<30 s) [58–60] (Fig. 4). Many other
studies have confirmed heterogeneous rates of disintegra-
tion [58]. Dissolution rates appear to have much less
variability [59–63].
In 2005, Epstein showed a greater irritant response in
dogs from a generic alendronate compared to the reference
product when tablets of the two formulations were placed at
the lower oesophagus: the differences were attributed to the
excipients, since the active ingredient (alendronate sodium)
and the dose in copy alendronate tablets were similar to
branded tablets [64].
Rapid disintegration with semi-particulate alendronate
may cause poor tolerance by adhering to the oesophageal
mucosa. Such an effect of a majority of generic formula-
tions of alendronate, but not the proprietary products, was
shown in vitro on the oesophageal mucosa of pigs [65]. All
but one of six generics displayed “cleavage” rupture
leaving a large piece of tablet strongly adherent to the
oesophageal mucosa.
Discussion
The evidence reviewed suggests that a high proportion of
generic formulations of alendronate and possibly other
bisphosphonates are associated with poorer tolerance and
more frequent and severe adverse events than the proprie-
tary compound. A plausible mechanism lies in the differ-
ences in the formulation of the excipients, rather than in the
content of active product. The finding of different disinte-
gration profiles and oesophageal bio-adhesiveness supports
this view and suggests that the safety profiles of the
different marketed tablets might be not be identical. It
Disintegration time (seconds)
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Fig. 4 Disintegration times in vitro of Fosamax 70-mg tablets (R) and
ten generic copies from South America [redrawn from 58]
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sample of generic products and that not all generic
bisphosphonates should necessarily be tarred with the same
brush.
This poses a challenge for regulators in the approval
process for generic products with known or suspected
upper gastrointestinal toxicity. Marketing authority is
usually based on bioequivalence with the presumption
of therapeutic equivalence, but this neglects the concerns
with safety highlighted in the present review. There is a
loophole in the current regulatory requirements for the
development of generic agents that exhibit gastrointesti-
nal side effects. We recommend that the approval process
for such agents should demand comparative studies of
gastrointestinal tolerance and safety in relevant target
populations. It is of interest that the Australian agency
has recently rejected a generic approval because of
uncertainties over safety [66].
Major consequences of poor tolerance are the impact of
side effects in patients that continue medication, poor
compliance and persistence and the decreased effectiveness
of treatment due to poor compliance and persistence. These
have implications for management guidelines and health
economic assessment.
Even small relatively modest side effects may have
implications for cost-effectiveness if their prevalence is
high among those that take the agent concerned. An
example is shown in Fig. 5 which shows the cost-
effectiveness of intervention as a function of the cost of
the agent. The lower line (reproduced in Fig. 1) is the
scenario where the incidence of long-standing side effects is
negligible. The upper curve shows the same clinical
scenario, but where long-standing intolerance reduces
quality of life on average by 1% compared to patients not
taking the drug. Under these assumptions, treatments
costing up to €450/year are within accepted bounds of
cost-effectiveness, but a product with significant side
effects would be cost-ineffective even with a drug price
tenfold lower at €45/year. In the absence of empirical data,
the scenarios are hypothetical, but illustrate the need for
such data and, in their absence, suggest that health
economic evaluations of generic bisphosphonates [22, 24,
28, 67] should be cautiously interpreted. Thus, despite firm
recommendations to introduce generic medication at treat-
ment initiation or to switch from brands to generic forms of
treatment [28], further health economic analyses with
generic specific data are required to confirm the validity
of such recommendation and quantify the real gain of
substituting generic formulations in place of branded
medications.
The impact of poor adherence (rather than side effects)
on cost-effectiveness is a relatively recent field of health
economics with the creation of models that capture the
elements of adherence [22, 68]. Poor persistence results in
lower costs and lower effectiveness so that the effects move
in the same direction and may have marginal impact on the
ratio of cost with effectiveness. This, however, neglects the
acquisition costs to identify the patient (BMD tests, visits to
a physician, etc.) so that cost-effectiveness is adversely
affected. The problem is compounded by poor compliance
when patients may take their bisphosphonate in a non-
fasting state or with calcium-containing liquids. Under
these circumstances, the cost remains the same (patients
take the drug), but the effectiveness is reduced. When
comparing full adherence with partial adherence, the
variables that on average had the greatest beneficial effect
on the incremental cost-effectiveness included the
efficacy of the intervention, drug price, underlying risk
of fractures, the fraction of benefit assigned to partial
adherence, and fracture-related costs. For example, a 1%
increase in drug effect lowered the incremental cost-
effectiveness ratio (ICER) by 2.2%, and a 1% increase
in the drug price of the high-adherence comparator
increased the ICER by 2.7% [69].
The principal effect of poor adherence is that it leaves
large groups of patients untreated, such that the public
health objectives of fracture reduction are not met.
Interventions that are associated with high adherence have
a considerable impact on the number of avoided fractures—
a feature that appears questionable in the case of generic
bisphosphonates.
Cost/QALY gained (€  € 000)
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Fig. 5 Cost-effectiveness of an agent according to price for a woman
from Sweden aged 65 years and a twofold increased risk of fracture.
The shaded area approximates the willingness to pay by NICE in the
UK. The lower slope (triangles) assumes no adverse effect of the
agent on quality of life, whereas the upper slope (squares) assumes a
1% decrease in quality of life due to adverse effects of the agent
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